SAN DIEGO--(BUSINESS WIRE)--Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying ...

Actio Biosciences, a clinical-stage biotechnology company advancing the translation of genetic insights into novel precision ...

SAN DIEGO, July 30, 2025--(BUSINESS WIRE)--Actio Biosciences, a clinical-stage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new therapeutics that ...

Actio Biosciences Announces Preclinical Data Highlighting Ability of ABS-1230 to Potently and Selectively Inhibit KCNT1 and Significantly Reduce Seizure Activity Data to be Presented During an Oral ...

SAN DIEGO, September 23, 2025--(BUSINESS WIRE)--Actio Biosciences, a clinical-stage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new small molecule ...

US-based Actio Biosciences has closed a Series B financing round, raising $66m to advance the genetics-driven small molecule therapeutics pipeline aimed at rare and common diseases. The funding will ...

Actio Biosciences to Present New Preclinical Data for ABS-1230, a KCNT1 Inhibitor for the Treatment of KCNT1-Related Epilepsy, at the American Epilepsy Society Annual Meeting Actio Biosciences, a ...

Actio Biosciences has administered the initial dose to a subject in the Phase Ia clinical trial of ABS-1230, a potassium sodium-activated channel subfamily T member 1 (KCNT1) inhibitor aimed at ...

“From one to many” is how Actio Biosciences Inc. describes its approach to drug development. The firm emerged with a $55 million series A financing and an eye for biological targets found in both rare ...

Investor syndicate comprised of leading healthcare investors, including Canaan, Deerfield Management, DROIA Ventures, EcoR1 and Euclidean Capital SAN DIEGO--(BUSINESS WIRE)--Actio Biosciences, a ...